Revolution Medicines (RVMD) Net Income towards Common Stockholders (2019 - 2026)

Revolution Medicines' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$453.8 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 112.64% year-over-year to -$453.8 million; the TTM figure through Mar 2026 stood at -$1.4 billion (down 96.66% YoY), while the FY2025 annual figure was -$1.1 billion, down 88.52% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$453.8 million, down from -$364.9 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$56.5 million in Q4 2022, with the low at -$453.8 million in Q1 2026.
• The 5-year median for Net Income towards Common Stockholders is -$133.2 million (2024), against an average of -$168.8 million.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders fell 7.31% in 2022, then plunged 185.77% in 2023.
• Revolution Medicines' Net Income towards Common Stockholders stood at -$56.5 million in 2022, then slumped by 185.77% to -$161.5 million in 2023, then decreased by 20.45% to -$194.6 million in 2024, then plunged by 87.54% to -$364.9 million in 2025, then retreated by 24.37% to -$453.8 million in 2026.
• Business Quant data shows RVMD's Net Income towards Common Stockholders at -$453.8 million in Q1 2026, -$364.9 million in Q4 2025, and -$305.2 million in Q3 2025.